Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 15:(199):10.3791/65068.
doi: 10.3791/65068.

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Affiliations

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Bisiayo E Fashemi et al. J Vis Exp. .

Abstract

Ovarian cancer is a fatal gynecologic cancer and the fifth leading cause of cancer death among women in the United States. Developing new drug treatments is crucial to advancing healthcare and improving patient outcomes. Organoids are in-vitro three-dimensional multicellular miniature organs. Patient-derived organoid (PDO) models of ovarian cancer may be optimal for drug screening because they more accurately recapitulate tissues of interest than two-dimensional cell culture models and are inexpensive compared to patient-derived xenografts. In addition, ovarian cancer PDOs mimic the variable tumor microenvironment and genetic background typically observed in ovarian cancer. Here, a method is described that can be used to test conventional and novel drugs on PDOs derived from ovarian cancer tissue and ascites. A luminescence-based adenosine triphosphate (ATP) assay is used to measure viability, growth rate, and drug sensitivity. Drug screens in PDOs can be completed in 7-10 days, depending on the rate of organoid formation and drug treatments.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:. Patient-derived organoids before drug screening.
(A) Experimental outline for PDO drug screen. Given the doubling time of the PDO line and the drug exposure time, the experimental plan may need to be adjusted. (B) Representative brightfield images (40x) of two ovarian cancer PDO lines (#1 and #2). Scale bar = 50 μm. Abbreviations: PDO = patient-derived organoids.
Figure 2:
Figure 2:. Representative results of ovarian cancer PDO following carboplatin treatment.
(A) Two PDO lines were treated with increasing concentrations of carboplatin for seven days. The X-axis shows carboplatin concentration; the Y-axis displays the % of live cells normalized to control organoids (no carboplatin). Assays were completed in triplicate with two biological replicates. The error bars denote the standard deviation. (B) GR-value graph representing the logarithmic carboplatin concentration (x-Axis) and the GR value (Y-Axis). These values were generated in the online GR calculator. The error bars indicate the standard deviation.

References

    1. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J m Karlan, B. Y. Ovarian cancer. Nature Reviews Disease Primers. 2 (1), 16061 (2016). - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 69 (1), 7–34 (2019). - PubMed
    1. Christie EL, Bowtell DDL Acquired chemotherapy resistance in ovarian cancer. Annals of Oncology. 28 (suppl_8), viii13–viii15 (2017). - PubMed
    1. Wang L, Wang Q, Xu Y, Cui M, Han L. Advances in the treatment of ovarian cancer using PARP inhibitors and the underlying mechanism of resistance. Current Drug Targets. 21 (2), 167–178 (2020). - PubMed
    1. Wang Q, Peng H, Qi X, Wu M, Zhao X. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduction and Targeted Therapy. 5 (1), 137 (2020). - PMC - PubMed

Publication types

LinkOut - more resources